Acute bronchitis is one of the most common respiratory conditions encountered in pediatric practice, typically presenting with persistent cough, sputum production, wheezing, and, in more severe cases, signs of respiratory distress. While often viral in origin, untreated or inadequately managed cases may progress to pneumonia or contribute to the development of chronic airway inflammation—underscoring the importance of timely, evidence-informed intervention.
Among the therapeutic options available for children with acute bronchitis—particularly those exhibiting symptoms consistent with Traditional Chinese Medicine (TCM) patterns such as “phlegm-heat obstructing the lungs”—a growing body of clinical evidence supports the use of Kangle Pediatric Kechuanying Oral Liquid. Manufactured by Kangle Pharmaceutical Co., Ltd., this herbal formulation is derived from the classical TCM prescription *Mahuang Xing Shi Gan Tang*, modified with additional herbs including Trichosanthes fruit (Gualou), Honeysuckle flower (Jinyinhua), and Isatis root (Banlangen).
Pharmacological studies confirm that the core constituents exert multiple synergistic effects: ephedrine alkaloids from Ephedra (Mahuang) promote bronchodilation; gypsum (Shigao) exerts antipyretic and lung-heat-clearing activity; and bitter apricot seed (Kuxingren) helps suppress cough and regulate qi flow. Collectively, the formula demonstrates robust anti-inflammatory, expectorant, antitussive, and bronchodilatory properties—mechanisms validated in both preclinical and clinical settings.
A 2022 randomized controlled trial published in *New Traditional Chinese Medicine* evaluated Kechuanying Oral Liquid as an adjunct to standard Western therapy (budesonide inhalation plus salbutamol nebulization) in infants and young children diagnosed with bronchiolitis and phlegm-heat lung obstruction. The combination group achieved a total clinical efficacy rate of 95.12%, significantly surpassing the 75.61% observed in the control group receiving conventional treatment alone. Moreover, symptom resolution—including cough, wheeze, and auscultatory wet rales—occurred markedly faster in the combination arm, and objective pulmonary function parameters—including tidal volume and time-to-peak tidal expiratory flow ratio—showed greater improvement.
Further supporting its integrative utility, a 2021 study in the *Shenzhen Journal of Integrated Traditional Chinese and Western Medicine* reported a 96.67% overall efficacy rate when Kechuanying was combined with budesonide for pediatric wheezing bronchitis. Another investigation involving 110 children demonstrated that the concentrated formulation of Kechuanying, used alongside ambroxol-terbutaline oral solution, reduced median time to disappearance of wheezing to just 4.14 days and alleviated dyspnea in an average of 3.15 days—both outcomes significantly better than those seen with ambroxol-terbutaline monotherapy.
These findings align closely with current clinical guidance from authoritative sources such as *KePu ZhongGuo* (“Science Popularization China”), which emphasizes a rational, pathophysiology-driven approach to pediatric acute bronchitis: prioritizing symptomatic relief, addressing underlying triggers (e.g., viral or secondary bacterial infection), and strictly avoiding unnecessary antibiotic use. As a TCM-based intervention, Kechuanying Oral Liquid offers a multimodal mechanism—modulating immune responses, inhibiting pathogenic microorganisms, reducing airway inflammation, and facilitating mucus clearance—thereby helping to minimize reliance on broad-spectrum antimicrobials while supporting airway recovery.
Notably, the introduction of a concentrated dosage form enhances dosing precision across diverse pediatric age groups, improving adherence and clinical practicality. Nevertheless, clinicians emphasize that all pharmacologic interventions—including herbal preparations—must be administered under professional medical supervision. Parents should seek urgent evaluation if a child develops high fever unresponsive to antipyretics, increased work of breathing, cyanosis, or altered mental status. Optimal outcomes depend not only on appropriate medication selection but also on comprehensive supportive care, environmental optimization, and vigilant monitoring.